Overall survival for patients with colorectal peritoneal carcinomatosis (PC) is dismal and typically averages around 6 months[@b1]. After the implementation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC), 5-year survival rates of up to 40% have been reported while some patients even appear to be cured[@b2][@b3][@b4]. Unfortunately, the majority of PC patients do not qualify for this aggressive treatment due to the presence of other distant metastases, a poor condition, advanced disease or other reasons. In these patients systemic treatment with palliative intent is used in increasing frequency[@b5].

Improvements in the systemic treatment of patients with metastatic colorectal cancer (mCRC) have resulted in extended survival. Currently, combining chemotherapy and targeted therapy is considered to be a standard of care for these patients[@b6][@b7]. However, no data from randomised controlled trials are available that have specifically addressed systemic treatment in PC patients. The sparse data available are derived from small subgroup analyses and population-based data[@b8][@b9][@b10]. Without exception, these studies show improved survival and support a role for modern combination therapy. These studies concern patients with synchronous PC where the primary tumor and PC were diagnosed simultaneously. However, in at least half of the patients, PC is diagnosed metachronously, after initial curative treatment for colorectal cancer[@b11]. So far, no data are available on the use and effect of palliative modern chemotherapy with or without targeted therapies in the latter group of patients. Therefore, the aim of the current population-based study is to investigate the use and effect of palliative systemic treatment in patients with metachronous PC of colorectal origin.

Methods
=======

Patient selection
-----------------

Data concerning patients presenting with metachronous PC of colorectal origin were extracted from the Eindhoven Cancer Registry that collects all data of patients with newly diagnosed cancer in the Southern part of the Netherlands[@b10]. This area comprises approximately 2.4 million inhabitants and has 10 community hospitals, 6 pathology departments and 2 radiotherapy institutions. All data are registered by trained registry managers who prospectively collect patient and tumor characteristics from medical charts.

Data on metachronous metastases were additionally collected between 2010 and 2011 for all patients who were diagnosed with M0 colorectal cancer between 2003 and 2008 in the Dutch Eindhoven Cancer Registry. Survival data were available until January 2014. Metachronous PC was defined as an interval of at least 3 months between primary tumor and PC diagnosis. Patient demographics and details concerning chemotherapeutic treatment and Bevacizumab (being the standard choice for targeted therapies at time of the current study) were collected and compared. Patients that underwent curative surgery for PC (CRS + HIPEC) were excluded from this study. Patients receiving targeted therapy prior to PC diagnosis and those who did not undergo a curative primary tumor resection were excluded from the analyses. Treatment and decisions were performed in accordance with national guidelines and regulations. The study protocol was approved and carried out in accordance with the Medical research Ethics Committees United (MEC-U).

Statistical analysis
--------------------

Patient and tumor characteristics were compared between patients with or without systemic treatment using the Chi square test. Next, the percentages of patients who additionally received Bevacizumab were calculated among those that received systemic treatment. Univariable and multivariable logistic regression analysis were used to identify predictors of treatment with Bevacizumab. Only variables with P \< 0.10 in the univariate analysis were included in the multivariable analysis. The predictors were depicted as odds ratios with their 95% confidence intervals. The effect of systemic treatment on mortality was investigated using multivariable cox regression analyses and depicted as hazard ratios. Survival was determined using the Kaplan-Meier method and compared using a Log-rank test. Survival was defined as time from diagnosis of PC to death or end of follow up period (January 2014). All tests were two sided and p-value \< 0.05 was considered to be significant. Statistical analyses were performed using SAS/STAT statistical software (SAS system 9.3, SAS Institute, Cary, North Carolina, USA).

Results
=======

Altogether, 1042 patients with primary colorectal cancer diagnosed between 2003 and 2008 developed metachronous metastases up until 2011. From these patients, 195 (19%) were diagnosed with metachronous PC and 101 among them (52%) received systemic treatment in a palliative setting. Nine of the latter patients were excluded from further analysis since they received targeted therapy prior to diagnosis of PC. Of the remaining patients, 36/92 patients (39%) received systemic treatment including Bevacizumab ([Fig. 1](#f1){ref-type="fig"}).

Treatment & patient characteristics
-----------------------------------

Patient and tumor characteristics were compared between patients with or without systemic treatment ([Table 1](#t1){ref-type="table"}). Patients receiving systemic treatment were younger than those receiving no treatment (67% vs. 31% with age \<70, P \< 0.01). Also, they displayed less comorbidities (48% vs. 68%, P \< 0.01) and were more often diagnosed with other distant metastases (65% vs. 50%, P = 0.04). Gender, tumor differentiation, location, histology or T and N-stage did not differ between the two groups.

[Table 2](#t2){ref-type="table"} shows the percentages of patient and tumor characteristics for those receiving additional Bevacizumab treatment among the total group of patients receiving systemic treatment. The multivariable odds ratios (OR's) are provided for variables with a P-value \< 0.10 in the univariate analysis. Among males, 51% received Bevacizumab compared to 26% among females (P = 0.01). In the age category below 70, 48% received Bevacizumab compared to 20% above 70 (P = 0.01). The group of patients without comorbidities received Bevacizumab more often (42% vs. 30%, P = 0.07). Regarding the primary tumor location, patients with left, right, rectum/rectosigmoid and overlapping/NOS as primary location received Bevacizumab in 60, 42, 30 and 33% of cases (P = 0.01).

The remaining factors tumor differentiation, histology, T-stage, N-stage and M-stage were not significantly different in the groups. Calculation of odds ratio's showed male gender to be a positive predictor (OR 2.68, 95% CI 1.0--7.4) and right sided primary tumor location (OR 0.20, 95% CI 0.1--0.6) to be a negative predictor for treatment with Bevacizumab.

Survival
--------

Median overall survival of the entire PC group was 7.2 months (95% CI 5.2--9.4 months). Median overall survival was only 3.4 months (95% CI 2.5--4.9 months) in patients who did not receive systemic treatment, 13.0 months (95% CI 9.5--16.0 months) for patients who received systemic chemotherapy only and 20.3 months (95% CI CI13.7--29.3 months) for patients treated with chemotherapy and Bevacizumab (P \< 0.001) ([Fig. 2](#f2){ref-type="fig"}). Next, survival of patients receiving chemotherapy was compared to patients receiving both chemotherapy and Bevacizumab with median survival being significantly longer in the group receiving both treatments (P = 0.04).

Predictors of death for patients with metachronous PC are shown in [Table 3](#t3){ref-type="table"} and presented as hazard ratios (HR). Age above 70 was associated with an increased risk of death (HR 1.86, 95% CI 1.29--2.68). The administration of both chemotherapy (HR 0.51, 95% CI 0.35--0.73) and chemotherapy with bevacizumab (HR 0.35, 95% CI 0.22--0.56) was associated with a decreased risk of death. When comparing chemotherapy only to chemotherapy and Bevacizumab, the hazard ratio was 0.69 (95% CI 0.42--1.12).

Discussion
==========

The data reported in this study suggest that palliative chemotherapy provided to patients diagnosed with metachronous peritoneal carcinomatosis of colorectal origin improved survival. Furthermore, the addition of Bevacizumab might improve survival even further.

While a positive effect of adding targeted therapy to chemotherapy has previously been established for synchronous PC[@b10], it remained unknown if such treatment would also benefit patients in the metachronous setting. These patients differ from the synchronous group since they have already undergone surgery for the primary tumor with curative intent and developed the metastases during follow up. Moreover, it has been shown that survival after metachronous metastases of colorectal origin is different compared to the synchronous setting with better results in the metachronous subgroup of patients[@b12]. This difference might be attributable to a more aggressive tumor biology in those patients presenting with synchronous metastases[@b13]. The current data showed that the addition of Bevacizumab to chemotherapy resulted in a median survival of 20 months compared to 13 months for patients treated with chemotherapy only. Bevacizumab was the standard choice of treatment for metastasised colorectal cancer during the course of this study and therefore the observed effect may be specifically attributed, at least in part, to this biological agent. However, several other factors which probably play a role in patient eligibility for the various palliative treatment options may affect outcome as well.

Metachronous PC is diagnosed in 4% of patients with colorectal carcinoma and is know to result in a median survival of only a few months[@b14][@b15][@b16]. The introduction of cytoreductive surgery and HIPEC during the last two decades has, in selected groups, resulted in a median survival of up to 60 months after diagnosis[@b17][@b18]. Unfortunately, the majority of patients cannot benefit from this particular treatment since patients have to be fit for surgery with limited peritoneal disease and an absence of distant metastases[@b19]. Therefore, additional palliative treatment options must be investigated for these patients.

The use of targeted monoclonal antibodies has improved overall and progression free survival in mCRC[@b20][@b21]. However, these improvements have been mainly demonstrated in patients with metastases to the liver or lung. These organs are well vascularised making intravenous chemotherapy readily available at these metastatic sites as opposed to peritoneal deposits, which are located in a more isolated part of the human body. Klaver *et al.* demonstrated this phenomenon by analysing two trials that included mCRC patients in the Netherlands[@b9]: the survival benefit of systemic chemotherapy with or without targeted therapies is significantly less in PC than in non-PC metastasized patients. A similar analysis by Franko *et al.* led to similar conclusions[@b8]. However, these trials have in common that a relatively small percentage of metastasized patients had PC.

Recently, results of treatment with chemotherapy and targeted therapies have also emerged specifically for PC. Zani *et al.* compared a PC group treated with modern chemotherapy including targeted therapies to a group treated with outdated regimens and showed an increased median survival of 16.3 vs. 8.9 months in the former[@b22]. Another recent study by Chua *et al.* described a cohort of 294 patients with PC in a palliative setting. Combination chemotherapy regimens (5-FU based with oxaliplatin or irinotecan) resulted in a median survival rate of 15 months compared to 11 months using single agent 5FU regimens[@b23]. Interestingly, median survival appeared to be further increased by adding targeted therapies such as bevacizumab, cetuximab or panitumumab, resulting in a median survival of 23 months. Both studies included a mixed population of metachronous and synchronous presentation of PC. In addition, similar findings have been reported in a synchronous PC only cohort, with an increased median survival of 10.1 to 18.2 months after the addition of targeted therapies[@b10].

Certain biases could not be evaded in the evaluation of the present cohort leading to a suggestion of increased survival when targeted therapies were added to palliative chemotherapy. The majority of patients receiving targeted therapies had less comorbidities and were younger, both conditions favouring enhanced survival. Nonetheless, in terms of hazard ratios, combining targeted therapies with chemotherapy proved to be a protective factor in multivariable analysis. However, when leaving out the patients who received no treatment, the addition of Bevacizumab did not significantly decrease the chance of death probably due to small sample size. Therefore the role of Bevacizumab in the treatment of metachronous PC from colorectal origin should be regarded as promising but needs further clinical investigation.

In addition, it stands to reason that considerations taken into account while deciding whether or not, to what extent and what type of chemotherapeutics and targeted therapies will be administered are patient and caretaker dependent[@b24]. Moreover, a significant proportion of patients had also other distant metastases. It is therefore uncertain to what extent increased survival can be attributed to the treatment of the peritoneal deposits in these patients, especially so since the effectiveness of targeted therapies in non-peritoneal metastases is supported by stronger evidence. Still, since many patients receive palliative treatment because of the presence of distant metastases they are a common phenomenon and therefore reflect clinical daily practice. Lastly, the extent of disease is impossible to assess since diagnostic modalities lack the ability to adequately estimate severance of disease. However, all patients were in a palliative setting, which means that either the patient condition wouldn't allow surgery, or the presence of either extra-abdominal metastases or severe intra-abdominal metastases made surgery contra-indicated.

To our knowledge, no studies have reported on the added value of Bevacizumab to palliative chemotherapy in patients with metachronous PC. The results of the current study suggest that treatment with palliative systemic chemotherapy especially in combination with Bevacizumab may significantly improve survival in these patients. However, due to the nature of this population-based study potential selection bias is inevitably and the results should therefore be interpreted cautiously.
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###### Patient and tumor characteristics in patients treated with and without systemic chemotherapy.

  Variable                  No systemic treatment (%)   Systemic treatment (%)    P-value
  ------------------------ --------------------------- ------------------------ ------------
                                     N = 94                     N = 92                
  Gender                                                                        
   Female                           54 (57.4)                 43 (46.7)             0.14
   Male                             40 (42.6)                 49 (53.3)               
  Age (years)                                                                   
   \<70                             29 (30.9)                 62 (67.4)          **\<0.01**
   \>70                             65 (69.1)                 30 (32.6)               
  Comorbidity                                                                   
   No                               30 (31.9)                 48 (52.2)          **\<0.01**
   Yes                              64 (68.1)                 44 (47.8)               
  Tumor differentiation                                                         
   Good                              4 (4.3)                   5 (5.4)              0.95
   Moderate                         53 (56.4)                 52 (56.5)               
   Poor/undifferentiated            23 (24.5)                 20 (21.7)               
   Unknown                          14 (14.9)                 15 (16.3)               
  Primary Location                                                              
   Left                             32 (34.0)                 41 (44.6)             0.10
   Right                            46 (48.9)                 37 (40.2)               
   Rectum/rectosigmoid              15 (16.0)                  9 (9.8)                
   Overlapping/NOS                   1 (1.1)                   5 (5.4)                
  Histology                                                                     
   Mucinous                         21 (22,3)                 26 (28.3)             0.62
   Adenocarcinoma                   70 (74.5)                 64 (69.6)               
   Signet ring cell                  2 (2.1)                   2 (2.2)                
   Unknown                           1 (1.1)                      0                   
  T-stage                                                                       
   T1,T2                             6 (6.4)                   3 (3.3)              0.57
   T3                               65 (69.1)                 68 (73.9)               
   T4                               23 (24.5)                 21 (22.8)               
  N-stage                                                                       
   N0                               29 (30.9)                 36 (39.1)             0.15
   N1                               31 (33.0)                 35 (38.0)               
   N2                               32 (34.0)                 21 (22.8)               
   NX                                2 (2.1)                      0                   
  M-status                                                                      
   PC only                          47 (50.0)                 32 (34.8)           **0.04**
   PC + distant                     47 (50.0)                 60 (65.2)               

###### Percentages and multivariable predictors of patients treated with Bevacizumab among those treated with systemic chemotherapy.

  Variable                  Systemic treatment   Bevacizumab (%)   Chi Square P-value       OR (95% CI)
  ------------------------ -------------------- ----------------- -------------------- ----------------------
  Gender                                                                               
   Female                           43              11 (25.6)           **0.01**              **ref**
   Male                             49              25 (51.0)                           **2.68 (1.0--7.4)**
  Age (years)                                                                          
   \<70                             62              30 (48.4)           **0.01**              **ref**
   \>70                             30               6 (20)                               0.37 (0.1--1.2)
  Comorbidity                                                                          
   No                               48              23 (41.8)           **0.07**              **ref**
   Yes                              44              13 (29.5)                             0.39 (0.1--1.2)
  Tumor differentiation                                                                
   Good                             5               3 (60.0)              0.56                    
   Moderate                         52              22 (42.3)                                     
   Poor/undifferentiated            20              6 (30.0)                                      
   Unknown                          15              5 (33.3)                                      
  Primary Location                                                                     
   Left                             41              21 (51.2)           **0.01**              **ref**
   Right                            37              7 (18.9)                            **0.20 (0.1---0.6)**
   Rectum/rectosigmoid              9               5 (55.6)                              0.72 (0.2--3.5)
   Overlapping/NOS                  5               3 (60.0)                              0.90 (0.1--6.7)
  Histology                                                                            
   Mucinous                         26              7 (19.4)              0.32                    
   Adenocarcinoma                   64              28 (43.8)                                     
   Signet ring cell                 2               1 (50.0)                                      
                                    0                                                             
  T-stage                                                                              
   T1,T2                            3               1 (33.3)              0.66                    
   T3                               68              25 (36.8)                                     
   T4                               21              10 (47.6)                                     
  N-stage                                                                              
   N0                               36              14 (38.9)             0.78                    
   N1                               35              15 (42.9)                                     
   N2                               21              7 (33.3)                                      
  M-status                                                                             
   PC only                          32              15 (68.2)             0.27                    
   PC + distant                     60              21 (35.0)                                     

OR: odds ratio. CI; confidence interval.

\*The included variables were determined based on univariate logistic regression variables with P \< 0.10.

###### Predictors of death among colorectal cancer patients with metachronous PC (COX-regression analyses).

  Variable                       Dead (%)   P-value         HR (95% CI)
  ----------------------------- ---------- ---------- -----------------------
  Gender                                              
   Male                            91.0       0.86              ref
   Female                          91.8                  1.13 (0.82--1.56)
  Age (years)                                         
   \<70                            86.8     **0.03**            ref
   \>70                            95.8                **1.86 (1.29--2.68)**
  Comorbidity                                         
   No                              88.5       0.22              ref
   Yes                             93.5                  1.18 (0.85--1.56)
  Primary tumor location                              
   Left                            90.4       0.76              ref
   Right                           91.6                  0.97 (0.68--1.37)
   Rectum/recto sigmoid            95.8                **1.73 (1.05--2.85)**
   Overlapping/NOS                 83.3                  1.76 (0.68--4.55)
  Systemic therapy                                    
   No systemic therapy             95.7       0.10              ref
   Chemotherapy only               87.5                **0.51 (0.35--0.73)**
   Chemotherapy + Bevacizumab      86.1                **0.35 (0.22--0.56)**

HR: odds ratio. CI; confidence interval.
